Article
Virus-like particles and capsomeres are potent vaccines against cutaneous alpha HPVs.
Department of Genome Modifications and Carcinogenesis, German Cancer Research Center, D-69120 Heidelberg, Germany.
Vaccine (impact factor:
3.77).
12/2009;
28(6):1583-93.
DOI:10.1016/j.vaccine.2009.11.048
pp.1583-93
Source: PubMed
-
Citations (0)
- Cited In (1)
-
Article: The natural history of human papillomavirus infections of the mucosal epithelia.
[show abstract] [hide abstract]
ABSTRACT: Human papillomaviruses (HPVs), members of a very large family of small DNA viruses, cause both benign papillomas and malignant tumors. While most research on these viruses over the past 30 years has focused on their oncogenic properties in the genital tract, they also play an important role in diseases of the upper aerodigestive tract. Rapidly accelerating advances in knowledge have increased our understanding of the biology of these viruses and this knowledge, in turn, is being applied to new approaches to prevent, diagnose, and treat HPV-induced diseases. In this introductory article, we provide an overview of the structure and life cycle of the mucosal HPVs and their interactions with their target tissues and cells. Finally, we provide our thoughts about treatments for HPV-induced diseases, present and future.Apmis 06/2010; 118(6-7):422-49. · 1.99 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
antibody responses
capsomeres
cutaneous genus alpha human papillomavirus
cutaneous HPV types
enhanced potential
four analyzed HPV types induced robust IFNgamma-associated T-cell activation
frequent causative agents
HPV 16 L1-based antigens
HPV-induced skin lesions
immunocompromised adults
L1-based particles
major burden
mice induced immune responses
neutralizing capacities
promising strategy
prophylactic vaccines
respective immunogen type
three types
vaccines
virus-like particles